Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
29,814,799
-
Share change
-
-1,227,917
-
Total reported value
-
$120,734,000
-
Price per share
-
$4.05
-
Number of holders
-
37
-
Value change
-
-$7,125,550
-
Number of buys
-
14
-
Number of sells
-
21
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2016
As of 31 Dec 2016,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,814,799 shares.
The largest 10 holders included
NEA Management Company, LLC, FMR LLC, Capital World Investors, BAILLIE GIFFORD & CO, FIL Ltd, ORBIMED ADVISORS LLC, Rock Springs Capital Management LP, MILLENNIUM MANAGEMENT LLC, QVT Financial LP, and Tekla Capital Management LLC.
This page lists
37
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.